MP25-14 THE TREATMENT OF CHRONIC ORCHALGIA WITH TMRTM: SUBSTANTIAL PAIN REDUCTION WITH DURABLE RESULTS

Abstract

You have accessJournal of UrologyInfections/Inflammation of the Genitourinary Tract: Prostate & Genitalia1 Apr 2015MP25-14 THE TREATMENT OF CHRONIC ORCHALGIA WITH TMRTM: SUBSTANTIAL PAIN REDUCTION WITH DURABLE RESULTS Daniel H. Shin, and Aaron Spitz Daniel H. ShinDaniel H. Shin More articles by this author , and Aaron SpitzAaron Spitz More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1217AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Chronic orchalgia is a common urological complaint with treatments ranging from medication to denervation and orchiectomy. Here we report our five year experience in the treatment of chronic orchalgia with Therapeutic Magnetic Resonance (TMRTM), an FDA approved device for the treatment of pain. With TMRTM, an electric current is applied for 10-20 minutes directly to the skin overlying the spermatic cord via two metal probes positioned on opposite sides of the scrotum, reportedly altering nerve cell ion conduction and the sensation of pain. METHODS Men with chronic orchalgia who had failed conservative management and were treated with TMRTM were identified and contacted. Demographic and pain data were collected and results were analyzed with T-test and one-way ANOVA to determine statistical difference. Patients reported pain levels using the numerical (zero-ten) pain scale, which has been validated to correspond measurably to severity of painful stimuli. RESULTS Forty-nine patients met criteria. Mean age was 50 years (range 22-82). Forty-five percent reported left testicular pain, 25% right testicular pain, and 29% bilateral. Mean duration of pain prior to TMRTM was 84 months (range 3-408). Etiology was 39% post-surgical (vasectomy, varicocelectomy, and hernia surgery), 28% idiopathic, and 20% associated with anatomic abnormality such as varicocele or epididymal cyst. Mean pain level prior to treatment (baseline) was 5.7 (range 1-10, n=36). After treatment, mean nadir pain level was 39% lower than baseline (3.5, range 0-8, n = 26, p < 0.005). On followup, mean reported pain level was 58% lower than baseline (2.4, range 0-7, n = 24, p < 0.005). Mean number of treatments received was 3.2 (range 1-14). Mean years since treatment to the followup was 2.75 years (range 0.5-4.9 years). No adverse effects were reported from treatment. There were no significant differences in degree of pain improvement when patients were stratified by etiology of orchalgia. CONCLUSIONS TMRTM represents an effective treatment for chronic orchalgia, with substantial reductions in reported pain levels, durable response, and no reported side effects. Limitations to our study include a small sample size, lack of a control group, and reliance of post-treatment pain data on patient recall. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e290 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Daniel H. Shin More articles by this author Aaron Spitz More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...